** Shares of drug developer Allakos ALLK.O rise 45.6% to 32 cents premarket
** Concentra Biosciences will buy Allakos for 33 cents per share in cash, a premium of 52% to ALLK's last close
** Allakos says a wholly owned subsidiary of Concentra will commence a tender offer by April 15 to acquire all outstanding shares of ALLK
** Co expects the deal to close in May 2025
** Says closing of the deal is subject to availability of at least $35.5 million of cash at closing, and other customary closing conditions
** Shares of the company have fallen 82.1% YTD
(Reporting by Sneha S K )
(( Sneha.SK@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。